Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07273838 · ClinicalTrials.gov registry record · Phase 2
Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
A Phase 2 study of Heart Failure and Acute Kidney Injury, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 2
- Study locations
NCT07273838: Recruiting Phase 2 study of Heart Failure and Acute Kidney Injury, sponsored by Yale University.
NCT07273838 is a Phase 2 study of Heart Failure and Acute Kidney Injury that is actively recruiting participants, run by Yale University. The registered enrollment target is 130 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07273838, a Phase 2 study of Heart Failure and Acute Kidney Injury, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 2
- Study locations
Study Summary
The overall objective of this study is to determine whether the addition of SGLT2 inhibitors to usual care in hospitalized patients with heart failure associated acute kidney injury is safe and efficacious. Investigators will assess if SGLT2 inhibition improves a composite cardio-renal outcome (mortality, dialysis, AKI progression, decongestion metrics, heart failure symptoms). Secondary objectives of this study are to compare individual components of the composite outcome as well as changes in biomarkers of kidney injury, inflammation, repair and oxidative stress between those exposed to the SGLT2 inhibitor vs placebo.
Primary Outcome
This outcome is assessed using a win ratio (total wins in the intervention group divided by total wins in the control group). Pairwise comparisons of predetermined components are made between each participant in the intervention and control group hierarchically in order of clinical importance, with a "win" assigned to the participant with the more favorable result at the first level of difference. The win ratio is the number of "winning" pairs for the treatment group divided by the number of "lo
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dapagliflozin 10mg Tab
Study Locations (2)
Connecticut
- Yale New Haven Hospital-St. Raphael Campus - New Haven
- Yale New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2026-03-05 |
| Est. Completion | 2029-10-31 |
| Phase | Phase 2 |
What NCT07273838 shows while recruiting
NCT07273838 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07273838 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT07273838 about?
NCT07273838 is a clinical study titled "Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome". The overall objective of this study is to determine whether the addition of SGLT2 inhibitors to usual care in hospitalized patients with heart failure associated acute kidney injury is safe and efficacious. Investigators will assess if SGLT2 inhibition improves a composite cardio-renal outcome (mort...
What is the current status of trial NCT07273838?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2026-03-05. Estimated completion is 2029-10-31.
What conditions does trial NCT07273838 study?
This clinical trial studies the following conditions: Heart Failure, Acute Kidney Injury.
What interventions are being tested in trial NCT07273838?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin 10mg Tab (DRUG).
Who is sponsoring clinical trial NCT07273838?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07273838 being conducted?
This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07273838's enrollment target sits among peer trials
130 196th of 397 higher than 200 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
RECRUITING · Phase 2
-
Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial
RECRUITING · Phase 2
-
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · Phase 2
-
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
RECRUITING · Phase 2
-
Metformin for Pulmonary Hypertension HFpEF
RECRUITING · Phase 2
-
The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
- NCT02708836 · 130 participants · NA
Limiting Emergence Phenomena After General Anesthesia With Combined LMA and ETT Airway Management Technique
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI